Showing 2131-2140 of 5274 results for "".
- Antihypertensive Drugs Linked to Increased Eczema in Elderlyhttps://practicaldermatology.com/news/antihypertensive-drugs-linked-increased-eczema-elderly/2463140/New research suggests that increased use of antihypertensive medications is associated with an increase in eczematous dermatitis. Researchers conducted a longitudinal cohort study in a population-based sample from primary care practices in The Health Improvement Network in the United Kingd
- Reflections on the “Clearly Me” Psoriasis Exhibithttps://practicaldermatology.com/news/reflecting-on-clearly-me-psoriasis-exhibit-a-qa-with-lindsay-adler/2463137/The “Clearly Me” exhibit in New York, New York, held from May 16-18, showcased real psoriatic patients through dynamic photographic portraits, captured by photographer L
- PHOTOS: "Clearly Me" NYC Event Highlights Psoriasis Journeys of Patientshttps://practicaldermatology.com/news/photos-clearly-me-nyc-event-highlights-psoriasis-journeys-patients/2463107/AbbVie recently held a dynamic, photo-centric event at High Line Nine Galleries in New York City highlighting the psoriasis journeys of several patients through photographs. The exhibit, called Clearly Me, aimed to raise awareness about psoriatic disease by telling the stories of these p
- Study: Apremilast Efficacy Shows Efficacy in Psoriasishttps://practicaldermatology.com/news/study-apremilast-efficacy-shows-efficacy-psoriasis/2463053/Results from a recent analysis suggest promise for apremilast, which showed efficacy in the treatment of patients with moderate-to-severe psoriasis. Authors publishing in Acta Dermato-Venereologica focused on the impact on skin lesions, pruritus, and serum cytokine levels. The r
- Merck Discontinues Testing of Experimental Skin Cancer Combo Therapyhttps://practicaldermatology.com/news/merck-discontinues-testing-experimental-skin-cancer-combo-therapy/2463022/Merck has announced the termination of the vibostolimab and pembrolizumab coformulation arm in the Phase 3 KeyVibe-010 trial, according to a news release from the company. The trial assessed the combination therapy's efficacy compared to KEYTRUDA alone as adjuvant treatment for patients w
- LEO Pharma Announces Topline Results of Phase 3 Trial in China for Plaque Psoriasis Treatment Enstilarhttps://practicaldermatology.com/news/leo-pharma-announces-topline-results-phase-3-trial-china-plaque-psoriasis-treatment-enstilar/2463007/LEO Pharma announced results from the Enstilar phase 3 trial in China in adult patients living with stable plaque psoriasis. The trial is a phase 3, randomised, investigator-blind, active controlled, parallel group, multicenter trial comparing the efficacy and safety of once daily Enstila
- Study: OTC Ointment Effective for Hydration and Wound Healing after Dermatologic Procedureshttps://practicaldermatology.com/news/otc-ointment-effective-hydration-wound-headling-dermatologic-procedures/2462940/Results from a two-study analysis in the Journal of Drugs in Dermatology suggested efficacy for an over-the-counter healing ointment (HO; Cetaphil Healing Ointment, Galderma Laboratories, LP, Dallas) in improving skin hydration and wound healing outcomes following dermatologic procedures
- Trifarotene Plus Skincare Effective Treatment for Acne-Induced Hyperpigmentationhttps://practicaldermatology.com/news/trifarotene-plus-skincare-effective-treatment-acne-induced-hyperpigmentation/2462920/Trifarotene combined with a skincare regimen was effective for the treatment of acne-induced hyperpigmentation (AIH) accompanying acne vulgaris (AV), according to results from a recent phase IV double-blind study. Researc
- LEVEL UP: Upadacitinib Shows Superior Efficacy in ADhttps://practicaldermatology.com/news/level-study-upadacitinib-shows-superior-efficacy-ad/2462870/New topline results evaluating the efficacy and safety of upadacitinib for adults and adolescents with moderate-to-severe atopic dermatitis (AD) who had an inadequate response to systemic therapy or when use of those therapies was inadvisable suggested that treatment with the drug was effective.<
- EPI Health Issues Voluntary Recall of Several Products Following Bankruptcyhttps://practicaldermatology.com/news/epi-health-issues-voluntary-recall-several-products-following-bankruptcy/2462869/EPI Health (Novan) is initiating a voluntary recall of various within-expiry human drug products as a result of the closures and discontinuation of the post-marketing quality, regulatory and pharmacovigilance activities for these marketed products. The moves comes after EPI filed Chapter 7 bankru